News Release

Printer Friendly VersionView printer-friendly version << Back



AcelRx to announce second quarter 2019 results and provide an update on the company's business on Monday, August 5th, 2019

REDWOOD CITY, Calif., Aug. 2, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Monday, August 5th, 2019. AcelRx management will host a live webcast and conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on August 5, 2019 to discuss the financial results and provide an update on the company's business.

The webcast is accessible by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link on the Investors home page. The webcast will be accompanied by a slide presentation.  A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of the company's website at www.acelrx.com.

Investors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4204 for international callers.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA®(sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso®(sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is an investigational drug and not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com.

AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) (PRNewsfoto/AcelRx Pharmaceuticals, Inc.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-to-announce-second-quarter-2019-results-and-provide-an-update-on-the-companys-business-on-monday-august-5th-2019-300895694.html

SOURCE AcelRx Pharmaceuticals, Inc.

Media, Theresa Dolge, Evoke, 215-928-2748, theresa.dolge@evokegroup.com, or Jessica Ross, Evoke, 215-928-2346, jessica.ross@evokegroup.com; or Investors, Raffi Asadorian, CFO, AcelRx, investors@acelrx.com; or Brian Korb, Solebury Trout, 646-378-2923, investors@acelrx.com